

FIGURE 2A

Potential humanized sequence based on IGHV3-23*01 acceptor framework (AbM CDR definition)
IGHV3-23*01 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSYYADSVKKG
RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK
Joining region IMGT J00256|IGHJ4*01|YFDYWGGGTLVTVSS

seq	10	20	30	40	50	60
AbM	10	20	30	40	50	ab
	b b b	p	p b b b	b b i i	i i b b	b
SB-3F9	EVKLVE	SGGGLV	KPGGSL	KLSCAAS	GFTFSSYAMS	WVRQTPEKRL
	*	*	*	*	*	*
IGHV3-23*01	EVQLLE	SGGGLV	QPGGSL	RRLSCAAS	GFTFSSYAMS	WVRQAPGKGLEWVS
hSB-3F9-H1	EVQLLE	SGGGLV	QPGGSL	RRLSCAAS	GFTFSSYAMS	WVRQAPGKGLEWVS
hSB-3F9-H2	EVQLLE	SGGGLV	QPGGSL	RRLSCAAS	GFTFSSYAMS	WVRQAPGKGLEWVA

seq	70	80	90	100	110	120
AbM	60	70	80	abc	90	100abcd
	i b	b b b x	b b b b	b i b i b b	i b b b	
SB-3F9	YPD	SVKGRFT	ISRDN	AKYTL	YLQMSS	LRSEDTAL
	*	*	*	*	*	*
IGHV3-23*01	YADSVKGR	FTISRDN	SKNTLYL	QMNSLRAEDT	AVYYCAK	
hSB-3F9-H1	YADSVKGR	FTISRDN	SKNTLYL	QMNSLRAEDT	AVYYCAK	PPYDDYGGGFAY
hSB-3F9-H1	YADSVKGR	FTISRDN	SKNTLYL	QMNSLRAEDT	AVYYCAK	PPYDDYGGGFAY

L

P

FIGURE 2B

Potential humanized sequence based on IGKV3-11*01 acceptor framework (AbM CDR definition)
IGKV3-11*01 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRA
GIPARFSGSGGTFTLTSSLEPEDFAVYYCQQRSNWEP
Joining region IMGT J00242|IGKJ2*01|YTFGGTKLEIK

seq	10	20	30	40	50	60
AbM	10	20	30abcd	40	50	
	b b b	p p	b b b	b b i	i i i	i
SB-3F9	DIVLTQSPASLA	VS	LG	Q	R	A
	T	S	C			
	*	*	*	*	*	*
3-11*01	EIVLTQSPATLSLSPGERATLSC	RASQSVS	----	SYLA	WYQKPGQAPRLLIY	DASNRA
hSB-3F9-L1	EIVLTQSPATLSLSPGERATLSC	RASKSVSSSGYSYMH	WYQKPGQAPRLLIY	LASNLES		
hSB-3F9-L2	EIVLTQSPATLSLSPGERATLSC	RASKSVSSSGYSYMH	WYQKPGQAPRLLIY	LASNLES		
hSB-3F9-L3	EIVLTQSPATLSLSPGERATLSC	RASKSVSSSGYSYMH	WYQKPGQAPRLLIY	LASNLES		

V P #

seq	70	80	90	100	110
AbM	60	70	80	90	100
	b b	b b b	b b b	i b i	b b b
SB-3F9	GVPARFSGSGGTFTLTNIHPVEE	DA	TY	YC	QHNREL
	P	C	T		
	*	*	*	*	*
3-11*01	GIPARFSGSGGTFTLTSSLEPEDFAVYYC	QQRSNWEP			
hSB-3F9-L1	GIPARFSGSGGTFTLTSSLEPEDFAVYYC	QHNREL	P	C	T
hSB-3F9-L2	GVPARFSGSGGTFTLTSSVEPEDFAVYYC	QHNREL	P	C	T
hSB-3F9-L3	GVPARFSGSGGTFTLTSSVEPEDFAVYYC	QHNREL	P	C	T

A # ^

FIGURE 3




FIGURE 4A





FIGURE 4B







FIGURE 5A

FIGURE 5B

FIGURE 6A





FIGURE 6B






FIGURE 7A




FIGURE 7B

FIGURE 8A




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 10A




FIGURE 10B




FIGURE 11B




FIGURE 11A




FIGURE 12B




FIGURE 12A




FIGURE 13B




FIGURE 14A




FIGURE 14B




FIGURE 15B




FIGURE 15A




FIGURE 16




FIGURE 17A




FIGURE 17B





FIGURE 17C






FIGURE 18A





FIGURE 18B

FIGURE 19A

Group	CD34+ HSC Donor A # mice	CD34+ HSC Donor B # mice	Antibody Treatment	Dose	Schedule	Inoculum
1	2	9	hulG1	10 mpk	q3dx2	3 million A375 cells
2	3	10	3F9-22 PS	10 mpk	q3dx2	3 million A375 cells
3	3	10	3F9-22 NSLF	10 mpk	q3dx2	3 million A375 cells

FIGURE 19B









FIGURE 21A




FIGURE 21B




FIGURE 22




FIGURE 23




FIGURE 24

